Longeveron, a leading stem cell research company focused on biological solutions for age-associated diseases, announced today the successful completion of enrollment in the first phase of its clinical research trial of Longeveron allogeneic human mesenchymal stem cells (LMSCs®) to treat Alzheimer’s disease.
The fifth and final patient needed for the initial safety “run-in” phase was infused last week. The Company will review the safety data prior to proceeding with the second phase: a 25-subject randomized, placebo-controlled, double-blind study evaluating the safety, tolerability and efficacy of LMSCs in early-stage Alzheimer’s disease. The trial is taking place at the University of Miami’s Miller School of Medicine.
“The impact of Alzheimer’s disease is vast, far exceeding the medical community’s current ability to treat it,” said Joshua M. Hare, M.D., Longeveron’s Co-Founder and Chief Science Officer. “Regenerative medicine and cell-based therapies offer a promising new approach to close this gap and address the urgent need for effective therapies to combat the condition.”
An important component in the progression of Alzheimer’s disease is neuroinflammation. Longeveron was recently awarded a $1 million Part the Cloud Challenge on Neuroinflammation grant from the Alzheimer’s Association to help support this research.
“Adult stem cells are very potent anti-inflammatories. The characteristic amyloid plaques found in the brains of Alzheimer’s disease patients produce inflammation, and stem cells can reduce inflammation,” explained Bernard S. Baumel, M.D., Principal Investigator for the trial. “Alzheimer’s also impairs the brain’s ability to adequately produce new brain cells in the memory area known as the hippocampus. Stem cells can stimulate the brain to produce these new cells needed to form memory. We believe that an infusion of LMSCs may improve the condition or at least halt the progression of the disease.”
For the full article, click here.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.